Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
I will try to summarize the report entitled "A Highly Durable RNAi Therapeutic Inhibitor of PCSK9"

" A recently discovered means of decreasing PCSK9 levels is the administration of small interfering RNA molecules."

They found "approximately 60% lowering of the serum LDL cholesterol level with peak effects lasting more than 30 days..."

" In the multiple dose phase, the most common adverse events (occurring in greater than 10% of the participants were headache 18% back pain and diarrhea in 15% and nasopharyngitis in 12%".

Their discussion included "clinical evidence that supports the ability of RNAi therapeutic agents in general to inhibit the synthesis of liver-derived target proteins." ..." inclisiran inhibits the synthesis of PCSK9 protein specifically in the liver" ..."the results must be regarded as preliminary and be confirmed in larger clinical trial of longer duration."

My take is that the science works, but it probably will be a long journey before it will be used in the general population. Not only will more studies need to be done, but the follow-up of the patients in terms of actually decreasing heart attacks will take a fairly long time.

Dr. Steve
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.